The cost-effectiveness of male HPV vaccination in the United States
Authors:
- Harrell W. ChessonHCHarrell W. Chesson
- Donatus U. EkwuemeDEDonatus U. Ekwueme
- Mona SaraiyaMSMona Saraiya
- Eileen F. DunneEDEileen F. Dunne
- Lauri E. MarkowitzLMLauri E. Markowitz
Abstract
No abstract availableKeywords
This publication has 31 references indexed in Scilit:
- Impact of vaccinating boys and men against HPV in the United StatesVaccine, 2010
- Cost effectiveness analysis of including boys in a human papillomavirus vaccination programme in the United StatesBMJ, 2009
- Economic Evaluation of Human Papillomavirus Vaccination in Developed CountriesPublic Health Genomics, 2009
- Health and Economic Implications of HPV Vaccination in the United StatesNew England Journal of Medicine, 2008
- Cost-effectiveness of Human Papillomavirus Vaccination in the United StatesEmerging Infectious Diseases, 2008
- Model for Assessing Human Papillomavirus Vaccination StrategiesEmerging Infectious Diseases, 2007
- Evaluating Human Papillomavirus Vaccination ProgramsEmerging Infectious Diseases, 2004
- Projected Clinical Benefits and Cost-effectiveness of a Human Papillomavirus 16/18 VaccineJNCI: Journal of the National Cancer Institute, 2004
- Potential Health and Economic Impact of Adding a Human Papillomavirus Vaccine to Screening ProgramsJAMA, 2003
- Cost Effectiveness of a Potential Vaccine forHuman papillomavirusEmerging Infectious Diseases, 2003